Atlantic Anti-Platelet Guidelines Panel Commentary Videos

• 

  Michael P. Love MD, MB, ChB, MRCP

  1. What drove the decision to create Atlantic acute coronary syndrome guideline?
  2. What body of clinical evidence did the Panel review and consider while forming the recommendations and how were subgroup analyses utilized?
  3. The AAPI Guideline primarily recommends a Selective vs. Universal approach to the use of the newer antiplatelet medications, what considerations influenced that decision?
  4. What body of evidence was used to support a switch between antiplatelet agents?
  5. What role do you foresee for Inter-Provincial clinical committees such as these during the reimbursement process?
  6. What are the key messages the Panel would like to share with Atlantic clinicians via the AAPI recommendations?
  Top

• 

  Vernon Paddock MD, FRCPC

  1. Why was there a need to create an Atlantic acute coronary syndrome guideline?
  2. What body of clinical evidence did the Panel review and consider during recommendation decision-making?
  3. What evidence was used to support a switch between antiplatelet agents?
  4. What role do you foresee for inter-Provincial clinical committees such as these during the reimbursement process?
  5. The AAPI Guideline primarily recommends a Selective vs. Universal approach when prescribing the newer antiplatelet medications, what factors influenced that decision?
  6. Appreciating there was consensus between AAPI Panel members, was there similar agreement by Secondary Panelists who reviewed the recommendations?
  7. Why do the AAPI recommendations differ from the National CCS Antiplatelet and ECS guidelines if each of the committee’s evaluated the same body of clinical evidence?
  Top

• 

  Barry Rose MD, FRCPC, FACC

  1. Why was there a need to create an Atlantic acute coronary syndrome guideline?
  2. The AAPI Guideline primarily recommends a Selective vs. Universal approach when using the newer antiplatelet medications, what considerations influenced that decision?
  3. What evidence was used to support a switch between antiplatelet medications?
  4. Appreciating there was consensus between AAPI Panel members, was there similar agreement by Secondary Panelists?
  5. What role do you foresee for Inter-Provincial clinical committees such as these during the reimbursement process?
  6. What are the key messages the Panel would like to share with Atlantic clinicians via the AAPI recommendations?
  Top

• 

  Michel D’Astou MD, FRCPC

  1. Pourquoi y avait-il un besoin de créer des lignes directrices sur les syndromes coronariens aigus (SCA) au Canada atlantique?
  2. Comment la région de l’Atlantique était-elle représentée dans la composition du comité AAPI?
  3. Du point de vue d’un cardiologue, comment qualifieriez-vous le processus d’élaboration des lignes directrices de l’AAPI?
  4. Pourquoi les recommandations de l’AAPI diffèrent-elles des lignes directrices nationales de la SCC sur les antiplaquettaires ainsi que celles de la SEC, étant donné que les mêmes preuves cliniques ont été évaluées?
  5. Il semblerait que vos recommandations visent principalement à appuyer l’utilisation continue de Clopidogrel chez les patients atteints du SCA au Canada atlantique. Compte tenu des données supérieures sur la mortalité, pourquoi les nouveaux antiplaquettaires n’ont-ils pas occupé une place plus importante dans les lignes directrices?
  6. Quels sont les messages clés que le comité voudrait transmettre aux cliniciens du Canada atlantique par l’entremise des recommandations de l'AAPI?
  Top

• 

  Mike Callaghan BSc. (Pharm)

  1. As a Hospital Pharmacist, how would you characterize the process through which these recommendations were generated?
  2. How do these recommendations impact care within and between hospitals throughout Atlantic Canada?
  3. Considering the mortality benefit, why did the Panel not recommended a broader use of the newer antiplatelet agents such as ticagrelor in emergency departments throughout Atlantic Canada?
  4. Considering clopidogrel’s inter-patient variability of antiplatelet effect and prominence of that molecule throughout the AAPI recommendations, how confident was your Panel with generic clopidogrel being prescribed for ACS patients?
  5. How do payers throughout Atlantic Canada view the AAPI recommendations?
  Top

• 

  Rachel Harris BSc. (Pharm), PharmD.

  1. As a Hospital Pharmacist, how would you describe the process through which these recommendations were generated?
  2. How do these recommendations impact care within and between hospitals throughout Atlantic Canada?
  3. Considering the mortality benefit, why did the Panel not recommended a broader use of the newer antiplatelet agents such as ticagrelor in emergency departments throughout Atlantic Canada?
  4. Considering clopidogrel’s established inter-patient variability and prominence of that molecule within the AAPI recommendations, how confident was your Panel with generic clopidogrel being prescribed for acute coronary syndrome patients?
  5. How do payers throughout Atlantic Canada view the AAPI recommendations?
  Top

• 

  Kim D Kelly BSc. (Pharm)

  1. As a Hospital Pharmacist, how would you describe the process through which these recommendations were generated?
  2. How do these recommendations impact care within and between hospitals throughout Atlantic Canada?
  3. Considering the mortality benefit, why did the Panel not recommended a broader use of the newer antiplatelet agents such as ticagrelor in emergency departments throughout Atlantic Canada?
  4. Considering clopidogrel’s established inter-patient variability and prominence of that molecule within the AAPI recommendations, how confident was your Panel with generic clopidogrel being prescribed for acute coronary syndrome patients?
  5. Do payers from throughout Atlantic Canada hold an opinion on the AAPI recommendations?
  Top

• 

  David Marr MD, FRCPC, FACC

  1. From a cardiologist’s perspective, how would you describe the guideline development process?
  2. Why did the Atlantic Cardiovascular Society decide to endorse this Initiative and what role did it play?
  3. Considering the common body of published clinical evidence, why do the AAPI recommendations differ from the National CCS Antiplatelet and ECS guidelines?
  4. What is the Provincial payer stance on the AAPI recommendations?
  5. What are the practical messages community physicians should consider when applying the AAPI recommendations?
  Top

• 

  Neil Pearce MD, FRCPC

  1. As a Cardiologist how would you portray the guideline development process?
  2. What body of clinical evidence did the Panel review and consider during the development of the recommendations?
  3. Why do the AAPI recommendations differ from the National CCS Antiplatelet and ESC guidelines if all of the committee’s evaluated the same body of clinical evidence?
  4. The AAPI Guideline primarily recommends a Selective vs. Universal approach with the newer antiplatelet medications, what considerations influenced that decision?
  5. What are the key messages the Panel conveyed to Atlantic clinicians via the AAPI recommendations?
  6. What is the Provincial payer stance on the AAPI recommendations?
  Top

• 

  Michael Scott

  1. How did you become involved with the AAPI Panel?
  2. What key insights did you observed during your participation in this guideline creation process?
  3. When reflecting upon the experience, what are the most relevant points you would share with the audience?
  Top

• 

  Scott Wilson MD, CCFP (EM)

  1. As an Emergency room physician, how would you characterize the process through which these recommendations were generated?
  2. How do these AAPI recommendations impact care within and between hospitals throughout Atlantic Canada?
  3. Considering the mortality benefit, why did the Panel not recommended a broader use of the newer antiplatelet agents such as ticagrelor in emergency departments throughout Atlantic Canada?
  4. What are the key messages the Panel conveyed to Emergency Department Physicians via the AAPI recommendations?
  Top

• 

  Stephanie Young BSc. (Pharm), ACPR, PharmD., MSc. (Med)

  1. As a Hospital Pharmacist, how would you describe the process through which these recommendations were generated?
  2. How do the AAPI recommendations impact care within and between hospitals throughout Atlantic Canada?
  3. Considering the mortality benefit, why did the Panel not recommended a broader use of the newer antiplatelet agents such as ticagrelor in emergency departments throughout Atlantic Canada?
  4. Considering clopidogrel’s established inter-patient variability, how confident was your Panel with recommending generic clopidogrel for Atlantic acute coronary syndrome patients?
  5. How do payers throughout Atlantic Canada view the AAPI recommendations?
  Top

• 

  Kevin McKenzie

  1. How did the project originate?
  2. How was the AAPI project funded?
  3. How did the Panel composition represent the Atlantic Region?
  4. What process was used to generate the AAPI recommendations?
  Top